Back to search

FORNY20-FORNY2020

Leads for treatment of inflammatory lung diseases (TILD_22)

Alternative title: Behandling av kronisk inflammatoriske lungesykdommer

Awarded: NOK 5.0 mill.

Project Number:

332415

Project Period:

2022 - 2024

Funding received from:

Location:

Chronic inflammatory lung disease is according to the World Health Organization one of the leading causes of death in the world and the number of cases is expected to increase over the next 30 years. Examples affecting numerous patients worldwide include chronic obstructive pulmonary disease and asthma, while cystic fibrosis is an example of a rarer and genetically determined disease. Such conditions are overall poorly treated with the existing therapies and there is a pressing need for new drugs that modulate the underlying lung inflammation and resulting tissue damage, rather than just providing symptomatic relief. These inflammatory conditions very often result in decreased quality of life followed by a significant load on relatives, with in addition an economical burden on society due to reduced labor and large health related costs. As a result of a long-term effort, funded through several programs within the Research Council of Norway and by the University of Bergen, researchers at the Department of Chemistry at the University of Bergen, have found molecules that can potentially be turned into a new oral drug for treatment of these diseases. These molecules could limit the deleterious action of neutrophil enzymes that are involved in the mechanisms underlying the diseases, and it is envisioned that this in turn could reduce tissue damage in the lungs. No such drugs are currently available on the market. The main objective of this specific verification project is to chemically synthesize a series of compounds that have suitable properties to be optimised towards a future medicine.

-

Funding scheme:

FORNY20-FORNY2020